Search Results
You are looking at 1 - 2 of 2 items for
- Author or Editor: Margaret A. Cawrse x
- Refine by Access: All Content x
Abstract
Objective—To determine aqueous humor flow rate in clinically normal dogs, using fluorophotometry.
Animals—20 clinically normal Beagles.
Procedure—A study was performed on 5 dogs to establish an optimal protocol for fluorophotometric determination of aqueous humor flow rate. This protocol then was used to measure aqueous humor flow rate in 15 dogs. Corneas were loaded with fluorescein by topical application, and corneal and aqueous humor fluorescein concentrations were measured 5, 6.5, and 8 hours after application. Concentration-versus- time plots were generated, and slopes and ratios of the fluorescein concentration in the cornea and aqueous humor from these graphs were used to calculate flow rates. Calculations were performed by use of automated software provided with the fluorophotometer and by manual computation, and the 2 calculation methods were compared.
Results—The protocol established for the 5 dogs resulted in semilogarithmic and parallel decay of corneal and aqueous humor concentrations. Manually calculated mean ± SD aqueous humor flow rates for left, right, and both eyes were 5.58 ± 2.42, 4.86 ± 2.49, and 5.22 ± 1.87 μl/min, respectively, whereas corresponding flow rates calculated by use of the automated software were 4.54 ± 3.08, 4.54 ± 3.10, and 4.54 ± 2.57 μl/min, respectively. Values for the left eye were significantly different between the 2 computation methods.
Conclusions and Clinical Relevance—Aqueous humor flow rates can be determined in dogs, using fluorophotometry. This technique can be used to assess pathologic states and medical and surgical treatments that alter aqueous humor dynamics. (Am J Vet Res 2001;62:853–858)
Abstract
Objective—To evaluate effects of topical application of a 2% solution of dorzolamide on intraocular pressure (IOP) and aqueous humor flow rate in clinically normal dogs.
Animals—15 Beagles.
Procedure—The IOP was measured in both eyes of all dogs for 3 days to determine baseline values. In a single-dose study, 50 μl of dorzolamide or control solution was applied in both eyes at 7:00 AM, and IOP was measured 7 times/d. In a multiple-dose study, dorzolamide or control solution was applied to both eyes 3 times/d for 6 days, and IOP was measured 4 times/d during treatment and for 5 days after cessation of treatment. Aqueous humor flow rate was measured for all dogs fluorophotometrically prior to treatment and during the multiple-dose study.
Results—In the single-dose study, dorzolamide significantly decreased IOP from 30 minutes to 6 hours after treatment. Mean decrease in IOP during this time span was 3.1 mm Hg (18.2%). Maximal decrease was detected 6 hours after treatment (3.8 mm Hg, 22.5%). In the multiple-dose study, dorzolamide decreased IOP at all time points, and maximal decrease was detected 3 hours after treatment (4.1 mm Hg, 24.3%). Mean aqueous humor flow rate decreased from 5.9 to 3.4 μl/min (43%) after treatment in the dorzolamide group.
Conclusions and Clinical Relevance—Topical application of a 2% solution of dorzolamide significantly decreases IOP and aqueous humor flow rate in clinically normal dogs. Therefore, topical administration of dorzolamide should be considered for the medical management of dogs with glaucoma. (Am J Vet Res 2001;62:859–863)
